768 results on '"Eisen, Andrea"'
Search Results
152. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update
153. Abstract OT-09-04: Analysis of genomic alterations in cell free DNA and gut bacterial diversity in metastatic breast cancer (MBC) patients on endocrine therapy: A pilot study
154. Abstract PS10-54: Single-centre retrospective study of treatment choices and outcomes of metastatic breast cancer post-progression on the CDK4/6 inhibitor palbobiclib
155. Abstract PS11-20: Radiation therapy (RT) induced toxicity in advanced breast cancer (ABC) patients treated with CDK4/6 inhibitors (CDK4/6is)
156. Abstract PS10-33: Analysis of factors associated with pathological complete response (pCR) in patients with HER2+ breast cancer receiving neoadjuvant chemotherapy
157. Abnormal screens among nonmutation carriers in the High Risk Ontario Breast Screening Program
158. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
159. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation
160. Clinical Management Recommendations for Surveillance and Risk-Reduction Strategies for Hereditary Breast and Ovarian Cancer Among Individuals Carrying a Deleterious BRCA1 or BRCA2 Mutation
161. Radiomics in Predicting Recurrence for Patients with Locally Advanced Breast Cancer using Quantitative Ultrasound
162. Memory complaints are associated with impaired working memory and reduced frontal cortical thickness in mid‐life surgically menopausal women
163. The relationship between the predicted risk of death and psychosocial functioning among women with early-stage breast cancer
164. The impact of having a sister diagnosed with breast cancer on cancer-related distress and breast cancer risk perception
165. The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele BRCA2 6174delT.
166. The risk of breast cancer in women with a BRCA1 mutation from North America and Poland
167. Quantitative ultrasound radiomics using texture derivatives in prediction of treatment response to neo-adjuvant chemotherapy for locally advanced breast cancer
168. Assessing burnout among oncologists in Ontario, Canada.
169. Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study
170. Impact of rarity on Canadian oncology health technology assessment and funding
171. Quantitative ultrasound radiomics for therapy response monitoring in patients with locally advanced breast cancer: Multi-institutional study results
172. Quantitative ultrasound radiomics in predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from multi‐institutional study
173. Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial
174. Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes
175. Abstract P5-08-08: Risk reducing mastectomy in average and high risk patients with locally advanced triple negative breast cancer
176. Assessing the risk of breast cancer
177. Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations
178. Determining the Cancer Diagnostic Interval Using Administrative Health Care Data in a Breast Cancer Cohort
179. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers
180. Systematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer
181. Additional file 3: of Predictors of mammographic density among women with a strong family history of breast cancer
182. Additional file 1: of Predictors of mammographic density among women with a strong family history of breast cancer
183. Validity of Models for Predicting BRCA1 and BRCA2 Mutations
184. Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in BRCA1/2-Associated Stage I/II Breast Cancer
185. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update
186. Characterization of BRCA1 and BRCA2 Mutations in a Large United States Sample
187. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers
188. Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group
189. Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study
190. A response to 'Personalised medicine and population health: breast and ovarian cancer'.
191. Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
192. Psychological consequences of MRI-based screening among women with strong family histories of breast cancer.
193. Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
194. Application of Breast Cancer Risk Prediction Models in Clinical Practice
195. Coaggregation of urogenital bacteria in vitro and in vivo
196. American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
197. Review: breast cancer is associated with a family history of the disease in first degree relatives
198. Prophylactic Mastectomy for Women with BRCA1 and BRCA2 Mutations - Facts and Controversy
199. Anthracycline Adjuvant Chemotherapy: How Much Is Enough?
200. Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.